GLP-1 pancreatitis explainer

The state of the evidence

When GLP-1 receptor agonists first reached the market for type 2 diabetes, post-marketing reports raised concern about pancreatitis risk. Subsequent large analyses produced a more mixed picture: some studies show a small increased risk, others show no significant increase versus other diabetes therapies. The signal is consistent enough that:

• Pancreatitis is listed as a recognised adverse effect on every GLP-1 product label (Wegovy, Mounjaro, Saxenda, Ozempic, Rybelsus).
• Prescribing information requires the prescriber to counsel patients on the red flags.
• Established history of pancreatitis is generally a reason to avoid GLP-1s.

Absolute risk for an individual patient remains low. The appropriate response is awareness and red-flag recognition, not avoidance of effective therapy on this basis alone.

Symptoms to recognise

• Severe persistent upper-abdominal pain. Often described as boring through to the back. Usually constant, severe, and worsening — not the intermittent crampy pain of typical GI side effects.
• Nausea and vomiting alongside the pain.
• Tenderness on light pressure to the upper abdomen.
• Fever.
• Rapid heart rate.
• In severe cases: jaundice, signs of shock.

The combination of severe persistent upper-abdominal pain with nausea is the picture to watch for. GLP-1 nausea on its own, without severe abdominal pain, is common and not the same picture.

What to do

1. Stop the GLP-1 medicine. Don’t take the next weekly injection (or daily dose) until you’ve been assessed.
2. Seek urgent medical care. NHS 111 for advice, 999 or A&E for severe pain. Tell them you’re on a GLP-1 medicine — the assessment changes accordingly.
3. Don’t restart the medicine until you’ve been cleared by a clinician. Even if pain settles on its own, restart should be a clinical decision.

If pancreatitis is confirmed

• Acute pancreatitis is typically managed with hospitalisation, pain control, IV fluids, and supportive care. Most cases resolve.
• GLP-1 therapy is generally not restarted after a confirmed pancreatitis episode. Alternative weight-management or diabetes therapies are considered.
• Underlying causes (gallstones, alcohol, lipid disorders) are often investigated to clarify whether the medicine or another cause was responsible.

Risk reduction

• Tell your prescriber about any history of pancreatitis or gallbladder disease.
• Tell your prescriber about heavy alcohol use, hypertriglyceridaemia, or other established pancreatitis risk factors.
• Don’t push the dose schedule faster than your prescriber and the medicine intend. Rapid weight loss is independently associated with gallstones, which can precipitate pancreatitis.